China's biopharma goes global: innovative drug NewCo partnership case

After revealing the "why" behind NewCo in our precious video, now let's examine the "how" through a landmark case: the Allist-ArriVent collaboration on furmonertinib. 

Their deal went beyond a simple license, creating a blueprint for global success. See the full case study on the latest VBtalk 👇

Watch the previous video: China's biopharma goes global: the NewCo model explained